RxDoctor Payments Data

Robert Winsett, DO

Pulmonary Disease · Live Oak, TXNPI 1841633153

Payments from drug & device makers

$1,748in general payments, 2019–2025

Across 81 payments — averaging $21.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inspire Medical Systems, Inc.$382
  • Boehringer Ingelheim$243
  • GSK$225
  • Insmed, Inc.$225
  • AstraZeneca$206
  • Merck$84
  • plus $383 from 13 others

What the payments were for

  • Food & beverage$1,56389%
  • Education$18611%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,748 in reported general payments places this provider in the 45th percentile of 904 pulmonary disease providers in Texas.

See all pulmonary disease providers in Texas

Medicare billing

Part B allowed, 2024
$196,797
Medicare patients
570
Services billed
2,059

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OpsumitMacitentan17$290,971
Trelegy ElliptaFluticasone/Umeclidin/Vilanter146$146,078
Breztri AerosphereBudesonide/Glycopyr/Formoterol61$82,669
Breo ElliptaFluticasone/Vilanterol84$52,389
Spiriva RespimatTiotropium Bromide27$33,170
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr30$26,584
Stiolto RespimatTiotropium Br/Olodaterol Hcl27$24,107
EliquisApixaban13$14,219
Fluticasone-SalmeterolFluticasone Propion/Salmeterol41$10,244
Advair HfaFluticasone Propion/Salmeterol13$8,489
Albuterol Sulfate HfaAlbuterol Sulfate127$5,148
SymbicortBudesonide/Formoterol Fumarate12$5,097
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate11$4,506
Wixela InhubFluticasone Propion/Salmeterol20$2,936
Montelukast Sodium87$876

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Opsumit$32$290,97117 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$225$225,050260 claims
AstraZenecaBreztri Aerosphere, Symbicort$206$87,76673 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$243$57,27754 claims
PfizerEliquis$38$14,21913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 904 pulmonary disease providers in Texas.

Other pulmonary disease in Live Oak

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →